USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: MOLECULAR DESIGN INTERNATIONAL, INC.
Address: 111 South Highland Street
MEMPHIS, TN 38111-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $521,596.00 7
SBIR Phase II $2,976,249.00 4
STTR Phase I $208,399.00 2

Award List:

TOPICAL PRODRUGS FOR TREATMENT OF ACNE AND SKIN DISEASES

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Harlie A. Parish , Principal Investigator
Award Amount: $50,000.00

TOPICAL PRODRUGS FOR TREATMENT OF ACNE AND SKIN DISEASES

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: Harlie A. Parish , Principal Investigator
Award Amount: $263,000.00
Abstract:
The long-term objective of this project is to develop a commercial product for the topical treatment of acne and skin diseases. the specific aim of the proposal is to invent a prodrug that can be used effectively and safely for the topical treatment of acne. since isotretinoin (13-cis-retinoic acid,… More

TOPICAL PRODRUGS FOR THE TREATMENT OF PSORIASIS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

TOPICAL PRODRUGS FOR THE TREATMENT OF PSORIASIS

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $500,000.00
Abstract:
Psoriasis is a disease that affects millions of americans with chronic recurrent exacerbations and remissions that areemotionally and physically debilitating. several treatmentsare available, but in many cases these are inadequate. this application is based on the premise that topical administration… More

DEVELOPMENT OF ELASTASE INHIBITORS TO TREAT EMPHYSEMA

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Parish, Harlie A , Principal Investigator
Award Amount: $50,000.00
Abstract:
The goal of this project is to develop a synthetic inhibitor of elastase that will be effective and safe in the treatment of emphysema. two different laboratories reported that chloromethyl ketone (cmk) is effective in animal models of emphysema. however, the cmk are too toxic for human use. we have… More

Alpha Adrenergic Agonists for CPR

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: William Purcell
Award Amount: $72,595.00
Abstract:
In the United States alone, approximately 450,000 people yearly suffer a cardiac arrest outsidethe hospital. Less than 10% of these patients are discharged from the hospital alive, and of these,approximately 60% suffer some form of permanent neurologic injury. The poor resuscitation rates… More

DEVELOPMENT OF MULTI-RECEPTOR LC STATIONARY PHASES

Award Year / Program / Phase: 2001 / STTR / Phase I
Agency: HHS
Research Institution: GEORGETOWN UNIVERSITY MEDICAL CENTER
Principal Investigator: Robert R. Clarke
Award Amount: $100,000.00
RI Contact: N/A
Abstract:
DESCRIPTION: (Applicant's description) Combinatorial methods for the synthesis of new drug substances require high throughput techniques for evaluation of structure-activity relationships. Microliter plates with immobilized target receptors can rapidly reduce thousands of… More

NON-IRRITATING RETINOIDS FOR THE TREATMENT OF AGING

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: William P. Purcell
Award Amount: $99,000.00
Abstract:
DESCRIPTION (provided by applicant): Molecular Design International, Inc. (MDI) has designed and synthesized three synthetic retinoids based on the removal of the free carboxylic acid proton and replacement with an ester moiety in 14-all trans retinoic acid (RA), 13-cis retinoic acid (13-cis RA)… More

NON-IRRITATING RETINOIDS FOR THE TREATMENT OF AGING

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: William P. Purcell
Award Amount: $1,016,500.00
Abstract:
DESCRIPTION (provided by applicant): This application represents the Phase II version of SBIR grant R43 AR049621 entitled "Non-Irritating Retinoids for the Treatment of Aging Skin". Studies carried out prior to Phase I and during the Phase I portion of this project have demonstrated that a synthetic… More

Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: William P. Purcell
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A major feature that distinguishes MDI 301 from RA is its lack of irritation… More

Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,196,749.00
Abstract:
DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A feature that distinguishes MDI 301 from RA is its lack of irritation when… More

Topical Skin Treatment to Facilitate Wound Healing in the Aged Population

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,001.00
Abstract:
DESCRIPTION (provided by applicant): MDI-301 is a synthetic retinoid. MDI-301, like RA, induces collagen synthesis and reduces expression of collagen-degrading matrix metalloproteinases in the skin. This agent also induces epidermal thickening. However, un like RA, MDI-301 is non-irritating when… More

Novel Topical Therapy for Diabetic Retinopathy using Beta-Adrenergic Receptor Ago

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF TENNESSEE HSC
Principal Investigator: Jena J. Steinle – 901-448-1910
Award Amount: $108,399.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of our work is to establish the potency and efficacy of a novel 2-adrenergic receptor agonist (compound 49b) in the prevention and/or reversal of non-proliferative diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness… More